Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Raza Ur Rehman, Bachelor of Medicine and Surgery at Shaikh Khalifa bin Zayed Al Nahyan Medical and Dental College, shared on LinkedIn:
”Publication Alert
Thrilled to share that our Open Access commentary has been published in Health science Reports (Wiley )
Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Health Science Reports | Volume 9, Issue 1
(e71702)
Raza Ur Rehman, Rida Fatima, Aymar AKILIMALI
Published: 29 December 2025
This article explores Fitusiran, a groundbreaking RNAi-based antithrombin-targeting therapy, marking a paradigm shift toward factor-independent prophylaxis in hemophilia management.
• Read here.
Honored to contribute to the evolving landscape of hemophilia therapeutics and RNA-based medicine.
Feedback and discussions are most welcome!”
Article: Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Authors: Raza Ur Rehman, Rida Fatima, Aymar Akilimali
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 22, 2026, 13:07Saneha Anjum Shaikh: Blood Bank Basics and Quality Control in Automation
-
Aug 22, 2026, 11:36Bernardo Gindri: How platelets Influence Cancer Progression
-
Aug 22, 2026, 11:34Nick Gehrig: Extending Platelet Shelf Life to Strengthen Blood Supply
-
Aug 22, 2026, 11:14Lei Yu: New Guidance for Acute Pulmonary Embolism in 2026
-
Aug 22, 2026, 11:01Neeraj Songara: Shelf-Stable Synthetic Blood – The Future of Emergency Transfusion?
-
Aug 22, 2026, 10:41Mike R.։ VTE Thrombectomy – Defining What Success Really Means
-
Aug 22, 2026, 10:28Steven Meier: What Happens During PRP Therapy?
-
Aug 22, 2026, 10:05Ralf Ludwig: When a Promising Biomarker Falls Short
-
Aug 22, 2026, 09:33Mary Cushman: What Causes PE to Happen in People with DVT?